Фармацевтичний журнал (Aug 2018)

Dynamics of prostate protectors assortment in the state formulary of medicines of 1-9 issues

  • І. V. Gadyak,
  • B. P. Hromovyk

DOI
https://doi.org/10.32352/0367-3057.5-6.17.01
Journal volume & issue
Vol. (5-6)
pp. 7 – 15

Abstract

Read online

Prostatitis is one of the most frequent urology diseases of men of reproductive age. Recommendations for rational pharmacotherapy prostatitis are included into the State Formulary of Medicines, which is reviewed and updated annually. Thus, the aim of our work was to study the dynamics of the assortment of prostate protectors.The State Formulary of Medicines of 1–9 issues and the State Register of Medicines of Ukraine dated 01. 08. 2017 were the materials of the research. The methods of search, content analysis, statistics, comparison and generalization were applied. It was established that the first, second and third issues of State Formulary of Medicines include three therapeutic and chemical subgroups of prostate protectors: alpha-adrenergic receptors antagonists (G04CA), testosterone-5-alpha reductase inhibitors (G04CB), other drugs used in benign prostatic hypertrophy (G04CX). And since the fourth issue – only the first two subgroups of prostate protectors were icnluded. Assortment prostate protectors was stabilized in State Formulary of Medicines of 8, 9 issues. Depth of assortment of the State Formulary of Medicines of the ninth issue is 55,8% in comparison with the State Register of Medicines of Ukraine along with 100% index for prostate protectors trade names based on alfuzosin, terazosin (G04CA – Аntagonists of alpha adrenergic receptors), finasteride and dutasteride (G04CB – Inhibitors of testosterone-5-alpha reductase), as well as the absence of drugs based on silodosin, dutasteride-tamsulosin, solifenacin-tamsulosin (G04CA – Antagonists of alpha-adrenergic receptors) and prostate protectors with G04CX – Other drugs used in benign prostatic hypertrophy.

Keywords